Rajnish Wellness Ltd (541601)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 7 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 13 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Rajnish Wellness Ltd reported Q2 FY27 results on 7 Nov 2026: revenue ₹16.4 Cr (+36.9% year on year, -47.0% on the previous quarter), and net profit ₹0.3 Cr (+439.5% year on year); the operating margin was 1.7%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹16.4 | +36.9% | -47.0% |
| செயல்பாட்டு லாபம் | ₹0.3 | நஷ்டத்திலிருந்து | +456.6% |
| நிகர லாபம் | ₹0.3 | +439.5% | +163.2% |
| EPS (₹) | 0.00 | — | +166.7% |
| செயல்பாட்டு லாப வரம்பு | 1.7% | — | — |
- லாபம் அதன் சொந்தப் போக்கை விட +979% மேலே
- செயல்பாட்டு லாப வரம்பு 351 bps YoY அதிகரித்தது
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹0.3 கோடி லாபத்தில், ₹0.3 கோடி (83%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹0.3 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹0.0 கோடியுடன் ஒப்பிடும்போது +979.0% ஆகும் (above trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Rajnish Wellness has entered into a strategic distribution partnership with JNTL Consumer Health (India) Pvt Ltd, part of Kenvue Inc. The company has been appointed as a distribution partner specifically for the Kalyan-Thane division. The tie-up covers major consumer brands including Johnson's Baby, Neutrogena, Listerine, Stayfree, and Benadryl. Financial terms, expected revenue, and margin contributions were not disclosed in the filing.
- Appointed distribution partner by JNTL Consumer Health (India) Pvt Ltd, operating under Kenvue Inc.
- Exclusive regional coverage for the Kalyan-Thane division handling brands like Johnson's Baby, Listerine, and Neutrogena.
- Designated dedicated warehouse facility located at Plot No. 18, Shankpal Niwas Sachin CHS, Kulgaon, Ambernath, District Thane.
- Financial metrics, minimum volume commitments, and deal value were not disclosed.
Rajnish Wellness Limited has announced the opening of 4 new franchise medical outlets under its 'Dava Discount' brand across West Bengal (Howrah, Purulia, North 24 Parganas, and Kolkata). The model provides consumers with up to 20% discount on branded medicines alongside free home delivery. Financially, the company generated Rs 168 Cr in TTM revenue with a net loss of Rs -5 Cr and operates with a very low promoter holding of 9.16%. The filing does not disclose revenue projections, capex, or franchise fees associated with these four stores.
- Opened 4 new franchise medical outlets in West Bengal under the 'Dava Discount' brand
- Stores located in Howrah (711316), Purulia (723133), North 24 Parganas (743126), and Kolkata (700161)
- Offers up to 20% discount on branded medicines with free home delivery
- Financial investment or expected store revenue was not disclosed
Rajnish Wellness reported standalone revenue from operations of ₹16.43 crore for Q2 FY27 (quarter ended September 30, 2026), up 36.8% YoY compared to ₹12.00 crore in Q2 FY26, but down 47.0% QoQ from ₹31.01 crore. Net profit for the quarter came in at ₹0.32 crore compared to ₹0.06 crore in the year-ago period and ₹0.12 crore in Q1 FY27. For H1 FY27, total revenue stood at ₹47.44 crore with a net profit of ₹0.45 crore. Operating cash flow remained negative at -₹5.88 crore for H1 FY27, driven primarily by a ₹14.60 crore increase in trade receivables.
- Revenue from operations rose 36.8% YoY to ₹1,642.54 lakhs (₹16.43 Cr) vs ₹1,200.42 lakhs in Q2 FY26
- Net profit increased to ₹32.37 lakhs (₹0.32 Cr) compared to ₹6.47 lakhs in Q2 FY26
- Sequential revenue declined 47.0% QoQ from ₹3,101.15 lakhs in Q1 FY27
- Net cash flow from operating activities stood at -₹587.80 lakhs for H1 FY27
- Trade receivables expanded significantly to ₹3,391.42 lakhs as of Sep 30, 2026, from ₹1,931.13 lakhs as of Mar 31, 2026
Rajnish Wellness Limited has announced the outcome of its Board Meeting held on August 31, 2026. The Board approved the Directors' Report and the 11th Annual Report for the financial year ended March 31, 2026. The 11th Annual General Meeting (AGM) will be held via Video Conferencing on Saturday, September 26, 2026, at 11:30 AM IST. The cut-off date for electronic voting entitlement is fixed for September 19, 2026, and the book closure window will be from September 20, 2026, to September 26, 2026.
- 11th Annual General Meeting scheduled for September 26, 2026, at 11:30 AM IST via VC/OAVM
- Cut-off date for e-voting eligibility set as Saturday, September 19, 2026
- Register of Members and Share Transfer Books closed from September 20, 2026, to September 26, 2026
- Approved Directors' Report and Annual Report for the financial year 2025-2026
Rajnish Wellness Ltd has submitted newspaper clippings of its unaudited financial results for the quarter ended June 30, 2026, as per SEBI (LODR) Regulations. The results were published in Active Times and Mumbai Lakshadeep following board approval on August 13, 2026. The company currently operates with a small market capitalization of Rs 36 Cr and a TTM revenue of Rs 142 Cr. Despite the revenue scale, the company remains loss-making with a TTM PAT of Rs -5 Cr and a negative operating margin of -5.8%.
- Board of Directors approved the Q1 FY27 unaudited results on August 13, 2026
- Results published in Active Times (English) and Mumbai Lakshadeep (Marathi) on August 14, 2026
- TTM Revenue of Rs 142 Cr is approximately 3.9x the current Market Cap of Rs 36 Cr
- Promoter holding remains critically low at 9.16% as of June 2026
- Company reported a net loss of Rs 4.7 Cr in the most recent March 2026 quarter
Rajnish Wellness reported a standalone net profit of Rs 12.30 Lacs for Q1 FY27, recovering from a significant loss of Rs 4.70 Cr in the preceding quarter. Revenue from operations stood at Rs 31.01 Cr, which is a sharp 69.6% decline from the Rs 101.95 Cr reported in Q4 FY26, though it remains up 580% YoY. The company's business model remains characterized by extremely thin margins, with stock-in-trade purchases (Rs 30.30 Cr) accounting for 97.7% of revenue. Total expenses for the quarter were Rs 30.97 Cr, resulting in a marginal profit before tax of Rs 12.30 Lacs.
- Net Profit of Rs 12.30 Lacs in Q1 FY27 vs a loss of Rs 4.70 Cr in Q4 FY26
- Revenue from operations fell 69.6% QoQ to Rs 31.01 Cr from Rs 101.95 Cr
- Purchases of stock-in-trade at Rs 30.30 Cr represent 97.7% of total revenue
- Paid-up equity share capital stands at Rs 101.53 Cr, significantly higher than the current market cap of Rs 36 Cr
- Earnings Per Share (EPS) improved to Rs 0.0012 from a negative Rs 0.05 in the previous quarter
Rajnish Wellness reported a return to profitability in Q1 FY27 with a net profit of ₹0.12 Cr, recovering from a loss of ₹4.70 Cr in the previous quarter. However, revenue saw a sharp sequential decline of 69.6%, falling to ₹31.01 Cr from ₹101.95 Cr in Q4 FY26. While YoY revenue growth appears high (up from ₹4.56 Cr), the business remains characterized by razor-thin margins, with stock-in-trade purchases consuming 97.7% of revenue. The company's market cap remains small at ₹36 Cr with a low promoter holding of 9.2%.
- Revenue from operations stood at ₹31.01 Cr for the quarter ended June 30, 2026.
- Net profit turned positive at ₹12.30 Lacs (₹0.12 Cr) versus a loss of ₹4.70 Cr in the preceding quarter.
- Sequential revenue declined by 69.6% from ₹101.95 Cr in the March 2026 quarter.
- Purchases of stock-in-trade accounted for ₹30.30 Cr, representing nearly the entire operating cost base.
- Earnings per share (EPS) for the quarter was reported at ₹0.0012.
Rajnish Wellness has scheduled a board meeting on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is coming off a volatile FY26 where revenue surged to Rs 142 Cr, but the company remained loss-making with a TTM PAT of Rs -5 Cr. Investors will be looking for margin recovery, as the operating profit margin stood at -5.8% for the trailing twelve months. The trading window for insiders has been closed since July 1, 2026.
- Board meeting scheduled for August 13, 2026, to approve IND-AS compliant results.
- Results pertain to the quarter ended June 30, 2026.
- Trading window closed from July 1, 2026, until 48 hours post-declaration.
- Company reported a significant revenue of Rs 101.95 Cr in the most recent March 2026 quarter.
- Promoter holding remains low at 9.16% as of June 2026.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
